A scanning electron micrograph of human sperm stuck together and immobilized by an antisperm antibody.
University of North Carolina Eshelman School of Pharmacy engineer ultra-potent sperm-binding monoclonal antibodies as option for affordable, non-hormonal female contraception
Scientists at the University of North Carolina at Chapel Hill are using the precision targeting of monoclonal antibodies for a new type of female contraception.
Monoclonal antibodies are known for their ability to fight off invading germs and are used to treat and prevent everything from cancer to COVID-19. Scientists are now looking at a new mission for antibodies: immobilizing sperm before it can reach an egg.
Carolina researchers have engineered ultra-potent antibodies that, during animal testing, effectively trapped and blocked more than 99.9% of human sperm. The promising study results published in Science Translational Medicine suggest contraceptives based on antibodies may offer women a non-hormonal option to prevent pregnancy.
“Many women avoid hormonal contraception because of real and perceived side effects,” said Samuel Lai, professor in the Division of Pharmacoengineering and Molecular Pharmaceutics at the UNC Eshelman School of Pharmacy.
These effects can include irregular bleeding, nausea, depression, weight gain and migraines. And for some women estrogen-based hormonal contraception can be harmful.
“There’s a major unmet need for alternative, non-hormonal contraceptives for women,” said Lai.
Antibodies as line of defense
Nearly half of all pregnancies in the United States are unintended, and Lai is among scientists across the country who are advancing the idea of using anti-sperm antibodies for contraception.
“We were inspired by infertility that occurs in some women who develop antibodies against their partner’s sperm,” said study first author Bhawana Shrestha, a doctoral student in the Department of Microbiology and Immunology at the UNC School of Medicine and graduate research assistant at the school of pharmacy.
The antibody they’re testing was isolated from an infertile woman and targets a unique surface antigen present on human sperm. When it’s added to sperm, the sperm quickly clump together.
“Using our highly multivalent IgG platform, we engineered antibodies that were more than 10 to 16 times more potent at agglutinating sperm and reducing sperm permeation through mucus than the best-known antibody,” she said.
Researchers explored the effect of antibodies in sheep, which have reproductive tracts similar to human females. At a high dose of 333 micrograms of antibody, both naturally occurring antibodies and the newly engineered antibodies, effectively stopped all human sperm motility, and at a low dose of 33.3 micrograms, the modified antibodies, but not the original ones, trapped 97% to 99% of sperm.
Next step: clinical trials
But monoclonal antibodies are known as expensive drugs, which puts their usefulness as an affordable contraceptive up in the air.
However, researchers believe that by increasing the potency, much lower doses of the multivalent antibodies may be needed for effective contraception.
“We think these second-generation molecules will provide not only greater potency but will translate to lower costs that make the approach cost-effective,” said Lai.
Mucommune, a startup spun out of the Lai Lab, has licensed the molecule for development of an antibody-based contraceptive. The company will focus on safety and manufacturing to prepare for human clinical trials that could start in 2023.
The team is working on incorporating the antibodies into an intravaginal ring that steadily releases the antibodies, or a dissolvable film placed in the vagina where it spreads antibodies before sex.
“By avoiding exogenous hormones and creating a women-controlled contraceptive method, we believe the antibodies developed here could meet the contraceptive needs for millions of women, help to reduce the number of unintended pregnancies and alleviate the health care costs of unintended pregnancies which some estimate to be in excess of $20 billion a year,” Lai said.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Non-hormonal female contraception
- Organon and Cirqle Biomedical Enter Research Collaboration and License Agreement for Investigational Non-hormonal, On-demand Contraceptive Candidateon July 28, 2022 at 4:30 am
Organon and Cirqle Biomedical Enter Research Collaboration and License Agreement for Investigational Non-hormonal, On-demand Contraceptive Candidate ...
- Why aren't there hormone-free birth control pills? Roe puts spotlight on contraceptiveson July 17, 2022 at 12:05 pm
“Hormonal birth control has barely changed since it was first discovered, and women want an alternative.” By some measures, there's no shortage of birth control. The Food and Drug ...
- VCF® female contraceptives is offering Free Samples to combat Roe v. Wade Decision by SCOTUSon July 12, 2022 at 2:15 pm
With limited access and even fewer options for non-hormonal birth control, VCF ® remains a trusted contraceptive option for women that is reimbursable under the Affordable Care Act and can be ...
- Female Contraception Post Roe V. Wade - Evofem CEO Saundra Pelletieron July 6, 2022 at 5:32 am
a non-hormonal female contraceptive. CEO Saundra Pelletier discusses investing implications of the Roe v Wade reversal. Breaking down EVFM’s strong growth rating despite poor profitability and ...
- U.S. abortion ruling ignites retail interest in women contraceptive makers - Vandaon July 1, 2022 at 10:04 am
July 1 (Reuters) - Retail investors have flocked to small biotech firms that make women contraceptives ... Evofem sells a non-hormonal contraception gel called Phexxi and Agile offers a weekly ...
Go deeper with Google Headlines on:
Non-hormonal female contraception
Go deeper with Bing News on:
Sperm-binding monoclonal antibodies
- Progress In The Search For Broadly Neutralizing Monoclonal Antibodies Von August 1, 2022 at 5:44 am
Antibodies from vaccines wane after a few months, antibodies from previous infections are often ineffective, and monoclonal therapies that worked against earlier variants struggle against current ...
- Antisperm Immunity and Infertilityon July 28, 2022 at 5:00 pm
located in the acrosomal compartment The anti-r-HSAP antibodies binded with human live sperm, and inhibited sperm binding/attachment in zona-free hamster penetration assay  Sptrx Sperm ...
- Cell Biology 2017on July 27, 2022 at 5:00 pm
Our first annual Cell Biology virtual event is now On-Demand! Join us in advancing basic biology and recent tools and techniques in cell research by coming together with like-minded colleagues. Cell ...
- Progress In The Search For Broadly Neutralizing Monoclonal Antibodies IIIon July 26, 2022 at 9:16 am
This is part of a continuing series describing antiviral antibodies to prevent and treat SARS-CoV-2 infections. In this series, we will discuss the fundamental nature of virus evolution, how ...
- Biocytogen and LiberoThera Achieve Milestone Progress in Co-Development of Fully Human GPCR Antibody Drugson July 20, 2022 at 5:02 pm
February 1 st 2021, Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) entered a strategic collaboration with LiberoThera Co., Ltd (“LiberoThera”) to co-develop fully human GPCR antibodies ...